Liver Transplant for Cholestatic Liver Diseases

Clinics in Liver Disease

Volumn 17, Issue 2, 2013, Pages 345-359

  Carrion, Andres F ^a   Bhamidimarri, Kalyan Ram ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cholestatic liver disease; Liver transplantation; Outcomes; Primary biliary cirrhosis; Primary sclerosing cholangitis; Recurrence

Indexed keywords

ALAGILLE SYNDROME; BILE DUCT ATRESIA; BILE DUCT CARCINOMA; BILIARY CIRRHOSIS; CHOLESTASIS; CHOLESTATIC LIVER DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CYSTIC FIBROSIS; END STAGE LIVER DISEASE; HUMAN; INTRAHEPATIC CHOLESTASIS; LIVER DISEASE; LIVER FIBROPOLYCYSTIC DISEASE; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; PRIMARY SCLEROSING CHOLANGITIS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SARCOIDOSIS; SCLEROSING CHOLANGITIS; SICKLE CELL; TREATMENT OUTCOME;

ALAGILLE SYNDROME; BILIARY ATRESIA; CHOLANGITIS, SCLEROSING; CHOLESTASIS; CHOLESTASIS, INTRAHEPATIC; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; PARENTERAL NUTRITION, TOTAL; PATIENT SELECTION; RECURRENCE; SARCOIDOSIS;

EID: 84875602320     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.12.005     Document Type: Review

References (94)

1. Molodecky N.A., Kareemi H., Parab R., et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011, 53(5):1590-1599.
2. Tischendorf J.J., Hecker H., Kruger M., et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007, 102(1):107-114.
3. Carbone M., Neuberger J. Liver transplantation in PBC and PSC: indications and disease recurrence. Clin Res Hepatol Gastroenterol 2011, 35(6-7):446-454.
4. Chapman R., Fevery J., Kalloo A., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51(2):660-678.
5. Freeman R.B., Gish R.G., Harper A., et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006, 12(12 Suppl 3):S128-S136.
6. Gores G.J., Gish R.G., Shrestha R., et al. Model for end-stage liver disease (MELD) exception for bacterial cholangitis. Liver Transpl 2006, 12(12 Suppl 3):S91-S92.
7. Goldberg D., Bittermann T., Makar G. Lack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis. Am J Transplant 2012, 12(6):1603-1609.
8. Burak K., Angulo P., Pasha T.M., et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99(3):523-526.
9. Bergquist A., Ekbom A., Olsson R., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36(3):321-327.
10. Nakeeb A., Pitt H.A., Sohn T.A., et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996, 224(4):463-473. [discussion: 473-5].
11. Eckel F., Jelic S. Biliary cancer: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl 4):46-48.
12. Rosen C.B., Heimbach J.K., Gores G.J. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008, 10(3):186-189.
13. Friman S., Foss A., Isoniemi H., et al. Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results. Scand J Gastroenterol 2011, 46(3):370-375.
14. Rea D.J., Heimbach J.K., Rosen C.B., et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005, 242(3):451-458. [discussion: 458-61].
15. Ibrahim S.M., Mulcahy M.F., Lewandowski R.J., et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008, 113(8):2119-2128.
16. Fosby B., Karlsen T.H., Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012, 18(1):1-15.
17. Kashyap R., Safadjou S., Chen R., et al. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases-an analysis of the UNOS database. J Gastrointest Surg 2010, 14(9):1362-1369.
18. Graziadei I.W., Wiesner R.H., Marotta P.J., et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999, 30(5):1121-1127.
19. Brandsaeter B., Friman S., Broome U., et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 2003, 38(11):1176-1183.
20. Alexander J., Lord J.D., Yeh M.M., et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008, 14(2):245-251.
21. Jeyarajah D.R., Netto G.J., Lee S.P., et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process?. Transplantation 1998, 66(10):1300-1306.
22. Papatheodoridis G.V., Hamilton M., Mistry P.K., et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998, 43(5):639-644.
23. Navaneethan U., Venkatesh P.G., Mukewar S., et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012, 10(5):540-546.
24. Adams D.H., Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006, 6(3):244-251.
25. Loftus E.V., Aguilar H.I., Sandborn W.J., et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998, 27(3):685-690.
26. Vera A., Gunson B.K., Ussatoff V., et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003, 75(12):1983-1988.
27. Trautwein C., Possienke M., Schlitt H.J., et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 2000, 95(9):2343-2351.
28. Rowe I.A., Webb K., Gunson B.K., et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008, 21(5):459-465.
29. Vera A., Moledina S., Gunson B., et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002, 360(9349):1943-1944.
30. Campsen J., Zimmerman M.A., Trotter J.F., et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008, 14(2):181-185.
31. Harrison R.F., Davies M.H., Neuberger J.M., et al. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis?. Hepatology 1994, 20(2):356-361.
32. Narumi S., Roberts J.P., Emond J.C., et al. Liver transplantation for sclerosing cholangitis. Hepatology 1995, 22(2):451-457.
33. Goss J.A., Shackleton C.R., Farmer D.G., et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997, 225(5):472-481. [discussion: 481-3].
34. Alabraba E., Nightingale P., Gunson B., et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009, 15(3):330-340.
35. Cholongitas E., Shusang V., Papatheodoridis G.V., et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008, 14(2):138-143.
36. Maheshwari A., Yoo H.Y., Thuluvath P.J. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004, 99(3):538-542.
37. Reese P.P., Yeh H., Thomasson A.M., et al. Transplant center volume and outcomes after liver retransplantation. Am J Transplant 2009, 9(2):309-317.
38. Akpinar E., Selvaggi G., Levi D., et al. Liver retransplantation of more than two grafts for recurrent failure. Transplantation 2009, 88(7):884-890.
39. Lindor K.D., Gershwin M.E., Poupon R., et al. Primary biliary cirrhosis. Hepatology 2009, 50(1):291-308.
40. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51(2):237-267.
41. Gong Y., Huang Z.B., Christensen E., et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2008, (3). CD000551.
42. Liermann Garcia R.F., Evangelista Garcia C., McMaster P., et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001, 33(1):22-27.
43. Eastell R., Dickson E.R., Hodgson S.F., et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991, 14(2):296-300.
44. Charatcharoenwitthaya P., Pimentel S., Talwalkar J.A., et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007, 13(9):1236-1245.
45. Sylvestre P.B., Batts K.P., Burgart L.J., et al. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl 2003, 9(10):1086-1093.
46. Neuberger J., Gunson B., Hubscher S., et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004, 10(4):488-491.
47. Sanchez E.Q., Levy M.F., Goldstein R.M., et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 2003, 76(11):1583-1588.
48. Corpechot C., Carrat F., Bahr A., et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005, 128(2):297-303.
49. Egawa H., Nakanuma Y., Maehara Y., et al. Disease recurrence plays a minor role as a cause for retransplantation after living-donor liver transplantation for primary biliary cirrhosis: a multicenter study in Japan. Hepatol Res 2012, [Epub ahead of print].
50. Kelly D.A. Intestinal failure-associated liver disease: what do we know today?. Gastroenterology 2006, 130(2 Suppl 1):S70-S77.
51. Nathan J.D., Rudolph J.A., Kocoshis S.A., et al. Isolated liver and multivisceral transplantation for total parenteral nutrition-related end-stage liver disease. J Pediatr Surg 2007, 42(1):143-147.
52. Horslen S.P., Sudan D.L., Iyer K.R., et al. Isolated liver transplantation in infants with end-stage liver disease associated with short bowel syndrome. Ann Surg 2002, 235(3):435-439.
53. Muiesan P., Dhawan A., Novelli M., et al. Isolated liver transplant and sequential small bowel transplantation for intestinal failure and related liver disease in children. Transplantation 2000, 69(11):2323-2326.
54. Diamond I.R., Wales P.W., Grant D.R., et al. Isolated liver transplantation in pediatric short bowel syndrome: is there a role?. J Pediatr Surg 2006, 41(5):955-959.
55. McKiernan P.J., Baker A.J., Kelly D.A. The frequency and outcome of biliary atresia in the UK and Ireland. Lancet 2000, 355(9197):25-29.
56. Yoon P.W., Bresee J.S., Olney R.S., et al. Epidemiology of biliary atresia: a population-based study. Pediatrics 1997, 99(3):376-382.
57. Karrer F.M., Lilly J.R., Stewart B.A., et al. Biliary atresia registry, 1976 to 1989. J Pediatr Surg 1990, 25(10):1076-1080. [discussion: 1081].
58. Nio M., Ohi R., Miyano T., et al. Five- and 10-year survival rates after surgery for biliary atresia: a report from the Japanese Biliary Atresia Registry. J Pediatr Surg 2003, 38(7):997-1000.
59. Serinet M.O., Broue P., Jacquemin E., et al. Management of patients with biliary atresia in France: results of a decentralized policy 1986-2002. Hepatology 2006, 44(1):75-84.
60. Schreiber R.A., Barker C.C., Roberts E.A., et al. Biliary atresia: the Canadian experience. J Pediatr 2007, 151(6):659-665. 665.e1.
61. Oh M., Hobeldin M., Chen T., et al. The Kasai procedure in the treatment of biliary atresia. J Pediatr Surg 1995, 30(7):1077-1080. [discussion: 1080-1].
62. Ryckman F., Fisher R., Pedersen S., et al. Improved survival in biliary atresia patients in the present era of liver transplantation. J Pediatr Surg 1993, 28(3):382-385. [discussion: 386].
63. Barshes N.R., Lee T.C., Balkrishnan R., et al. Orthotopic liver transplantation for biliary atresia: the U.S. experience. Liver Transpl 2005, 11(10):1193-1200.
64. Roberts J.P., Hulbert-Shearon T.E., Merion R.M., et al. Influence of graft type on outcomes after pediatric liver transplantation. Am J Transplant 2004, 4(3):373-377.
65. Kiuchi T., Kasahara M., Uryuhara K., et al. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 1999, 67(2):321-327.
66. Kasahara M., Kiuchi T., Inomata Y., et al. Living-related liver transplantation for Alagille syndrome. Transplantation 2003, 75(12):2147-2150.
67. Ovaert C., Germeau C., Barrea C., et al. Elevated right ventricular pressures are not a contraindication to liver transplantation in Alagille syndrome. Transplantation 2001, 72(2):345-347.
68. Kamath B.M., Schwarz K.B., Hadzic N. Alagille syndrome and liver transplantation. J Pediatr Gastroenterol Nutr 2010, 50(1):11-15.
69. Shneider B.L. Genetic cholestasis syndromes. J Pediatr Gastroenterol Nutr 1999, 28(2):124-131.
70. Davit-Spraul A., Gonzales E., Baussan C., et al. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 2009, 4:1.
71. Milkiewicz P., Wunsch E., Elias E. Liver transplantation in chronic cholestatic conditions. Front Biosci 2012, 17:959-969.
72. Beuers U., Rust C. Overlap syndromes. Semin Liver Dis 2005, 25(3):311-320.
73. Lalwani N., Bhargava P., Chintapalli K.N., et al. Current update on primary and secondary sclerosing cholangitis. Curr Probl Diagn Radiol 2011, 40(6):248-261.
74. Vanatta J.M., Modanlou K.A., Dean A.G., et al. Outcomes of orthotopic liver transplantation for hepatic sarcoidosis: an analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network data files for a comparative study with cholestatic liver diseases. Liver Transpl 2011, 17(9):1027-1034.
75. Casavilla F.A., Gordon R., Wright H.I., et al. Clinical course after liver transplantation in patients with sarcoidosis. Ann Intern Med 1993, 118(11):865-866.
76. Lipson E.J., Fiel M.I., Florman S.S., et al. Patient and graft outcomes following liver transplantation for sarcoidosis. Clin Transplant 2005, 19(4):487-491.
77. Bartlett J.R., Friedman K.J., Ling S.C., et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009, 302(10):1076-1083.
78. Molmenti E.P., Squires R.H., Nagata D., et al. Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transplant 2003, 7(2):93-97.
79. Debray D., Kelly D., Houwen R., et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011, 10(Suppl 2):S29-S36.
80. Fridell J.A., Bond G.J., Mazariegos G.V., et al. Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center's experience. J Pediatr Surg 2003, 38(8):1152-1156.
81. Couetil J.P., Houssin D.P., Soubrane O., et al. Combined lung and liver transplantation in patients with cystic fibrosis. A 4 1/2-year experience. J Thorac Cardiovasc Surg 1995, 110(5):1415-1422. [discussion: 1422-3].
82. Couetil J.P., Soubrane O., Houssin D.P., et al. Combined heart-lung-liver, double lung-liver, and isolated liver transplantation for cystic fibrosis in children. Transpl Int 1997, 10(1):33-39.
83. Castro O., Rana S.R., Bang K.M., et al. Age and prevalence of sickle-cell trait in a large ambulatory population. Genet Epidemiol 1987, 4(4):307-311.
84. Ebert E.C., Nagar M., Hagspiel K.D. Gastrointestinal and hepatic complications of sickle cell disease. Clin Gastroenterol Hepatol 2010, 8(6):483-489. [quiz: e70].
85. Banerjee S., Owen C., Chopra S. Sickle cell hepatopathy. Hepatology 2001, 33(5):1021-1028.
86. Schubert T.T. Hepatobiliary system in sickle cell disease. Gastroenterology 1986, 90(6):2013-2021.
87. Shao S.H., Orringer E.P. Sickle cell intrahepatic cholestasis: approach to a difficult problem. Am J Gastroenterol 1995, 90(11):2048-2050.
88. Mekeel K.L., Langham M.R., Gonzalez-Peralta R., et al. Liver transplantation in children with sickle-cell disease. Liver Transpl 2007, 13(4):505-508.
89. Summerfield J.A., Nagafuchi Y., Sherlock S., et al. Hepatobiliary fibropolycystic diseases. A clinical and histological review of 51 patients. J Hepatol 1986, 2(2):141-156.
90. Desmet V.J. What is congenital hepatic fibrosis?. Histopathology 1992, 20(6):465-477.
91. Millwala F., Segev D.L., Thuluvath P.J. Caroli's disease and outcomes after liver transplantation. Liver Transpl 2008, 14(1):11-17.
92. Kassahun W.T., Kahn T., Wittekind C., et al. Caroli's disease: liver resection and liver transplantation. Experience in 33 patients. Surgery 2005, 138(5):888-898.
93. Habib S., Shakil O., Couto O.F., et al. Caroli's disease and orthotopic liver transplantation. Liver Transpl 2006, 12(3):416-421.
94. De Kerckhove L., De Meyer M., Verbaandert C., et al. The place of liver transplantation in Caroli's disease and syndrome. Transpl Int 2006, 19(5):381-388.